Sponsor or institution
Clinical trials and research at Jiangsu Cancer Institute & Hospital
As of November 12, 2026, Find a Trial lists 8 clinical trials run by Jiangsu Cancer Institute & Hospital that are recruiting, in China. By phase: Phase 2 (7). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 8Clinical trials
- 1Country
Newest trials
All recruiting trials (8)
-
First-line therapy for advanced TNBC with QL1706, plus anlotinib and nab-paclitaxel
This study tests whether a combination of QL1706 with anlotinib and nab-paclitaxel can help people with newly diagnosed, advanced triple-negative breast cancer.
-
Short-course definitive chemoradiotherapy with camrelizumab for locally advanced unresectable esophageal squamous cell carcinoma
This trial sees if adding camrelizumab to short-course chemoradiotherapy—given either during treatment and continued afterwards or given only as maintenance afterwards—improves tumor response and survival for adults with locally advanced unresectable esophageal squamous cell carcinoma.
-
Oral paclitaxel combined with radiotherapy for locally advanced unresectable esophageal squamous cell carcinoma
This trial will try taking oral paclitaxel together with radiotherapy to treat people with locally advanced, unresectable esophageal squamous cell carcinoma who are elderly or cannot tolerate intravenous chemotherapy.
-
Perioperative chemo with low-dose radiotherapy and tislelizumab for locally advanced gastric/GEJ cancer
This trial tests whether adding low-dose radiotherapy and tislelizumab to perioperative chemotherapy helps people with resectable locally advanced gastric or gastroesophageal junction cancer.
-
Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer
This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.
-
Combining two immunotherapy drugs with chemotherapy for stage III unresectable non-small cell lung cancer
This study will test whether giving an anti-PD-1 and an anti-CTLA-4 drug together with paclitaxel polymer micelles and platinum chemotherapy helps people with stage III unresectable non-small cell lung cancer shrink tumors and become eligible for local treatment.
-
Combining Adebrelimab with Chemoradiotherapy and Surgery for Gastric Cancer
This study is testing if adding a new immunotherapy drug called Adebrelimab to standard treatments for stomach cancer can help patients with advanced cases do better and have a better chance of recovery.
-
Prognosis prediction and treatment for non-small cell lung cancer using blood tests
This study is trying to see if blood tests can help predict outcomes and guide treatment for patients with stage IIA-IIIC non-small cell lung cancer.
Quick answers
How many clinical trials run by Jiangsu Cancer Institute & Hospital are recruiting right now?
8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 7. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.